Edwards Lifesciences (EW)
(Delayed Data from NYSE)
$68.54 USD
+4.00 (6.20%)
Updated Oct 8, 2024 04:00 PM ET
After-Market: $68.53 -0.01 (-0.01%) 7:58 PM ET
3-Hold of 5 3
C Value F Growth F Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$68.54 USD
+4.00 (6.20%)
Updated Oct 8, 2024 04:00 PM ET
After-Market: $68.53 -0.01 (-0.01%) 7:58 PM ET
3-Hold of 5 3
C Value F Growth F Momentum F VGM
Zacks News
HOLX vs. EW: Which Stock Is the Better Value Option?
by Zacks Equity Research
HOLX vs. EW: Which Stock Is the Better Value Option?
Bull of the Day: Penumbra (PEN)
by Kevin Cook
This $4 billion innovator removes blood clots and the deadly shadow of stroke with catheter-based aspiration technologies
Masimo Gets CE Mark for ANI Module, Enhances Root Platform
by Zacks Equity Research
Masimo (MASI) obtains CE mark of the ANI module for the Masimo Root Patient Monitoring and Connectivity Hub, which is likely to strengthen its expanding Root platform.
Edwards Lifesciences (EW) Q1 Earnings Beat, EPS View Raised
by Zacks Equity Research
Edwards Lifesciences (EW) gains on strong segmental contributions in Q1.
Edwards Lifesciences Takes Over CAS Medical Systems for $100M
by Zacks Equity Research
This CASMED acquisition is expected to strengthen Edwards Lifesciences' (EW) critical care portfolio and expand its footprint in the smart monitoring technology market.
What's in Store for Edwards Lifesciences' (EW) Q1 Earnings?
by Zacks Equity Research
Edwards Lifesciences (EW) expects to gain from core Critical Care product group in Q1.
Edwards Lifesciences (EW) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Edwards Lifesciences (EW) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Can Retail Pharmacy USA Lift Walgreens' (WBA) Q2 Earnings?
by Zacks Equity Research
Widening pharmacy network, healthy prescription volumes along with contributions from Rite Aid are expected to contribute to Walgreens Boots' (WBA) top line in the fiscal second quarter.
Should John Hancock Multifactor Mid Cap ETF (JHMM) Be on Your Investing Radar?
by Sweta Killa
Style Box ETF report for JHMM
Edwards Lifesciences Presents Positive Partner 3 Trial Data
by Zacks Equity Research
Edwards Lifesciences (EW) expects SAPIEN 3 to gain FDA approval for the low-risk indication in late-2019.
Zacks Market Edge Highlights: Edwards Lifesciences, Exact Sciences, Aimmune Therapeutics, Allergan and Evolus
by Zacks Equity Research
Zacks Market Edge Highlights: Edwards Lifesciences, Exact Sciences, Aimmune Therapeutics, Allergan and Evolus
NASH, Allergies and Beauty Stocks: Invest or Not?
by Tracey Ryniec
There's a lot of innovation going on at the biopharmaceutical companies but which areas should investors be targeting?
Medtronic (MDT) Releases Encouraging Evalut TAVR Result
by Zacks Equity Research
Medtronic's (MDT) clinical study data shows that the low-risk aortic stenosis patients have special characteristics as they tend to be younger and active compared with the higher-risk equivalents.
Edwards Lifesciences (EW) Looks Good: Stock Adds 6.2% in Session
by Zacks Equity Research
Edwards Lifesciences (EW) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.
Company News For Mar 19, 2019
by Zacks Equity Research
Companies in the news are: OSTK, FIS, WP, EW and DERM
Edwards Lifesciences Makes Investments in Heart Failure Space
by Zacks Equity Research
The two transactions align with Edwards Lifesciences' (EW) goal of making the most innovative medical care available to patients of structural heart disease.
Edwards Lifesciences to Buy CASMED to Boost Critical Care Arm
by Zacks Equity Research
The CASMED buyout is expected to strengthen Edwards Lifesciences' (EW) position in smart monitoring technologies and boost top-line contributions from the Critical Care arm.
Should John Hancock Multifactor Mid Cap ETF (JHMM) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for JHMM
Edwards Lifesciences (EW) Q4 Earnings In Line, Revenues Top
by Zacks Equity Research
Edwards Lifesciences (EW) Q4 results benefit from growth in all the businesses.
Edwards Lifesciences (EW) Q4 Earnings Meet Estimates
by Zacks Equity Research
Edwards Lifesciences (EW) delivered earnings and revenue surprises of 0.00% and 0.41%, respectively, for the quarter ended December 2018. Do the numbers hold clues to what lies ahead for the stock?
Medical Products' Earnings Lineup for Jan 31: EW, BAX & More
by Zacks Equity Research
Let's take a look at the factors that are likely to influence the earnings results of a few Medical Products bigwigs within the broader Medical space.
What's in Store for Edwards Lifesciences' (EW) Q4 Earnings?
by Zacks Equity Research
Edwards Lifesciences (EW) expected to see consistent performance by Surgical Structural Heart and Critical Care segments in Q4.
Edwards Lifesciences (EW) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Edwards Lifesciences (EW) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Should John Hancock Multifactor Mid Cap ETF (JHMM) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for JHMM
Can Edwards Lifesciences (EW) Keep the Earnings Surprise Streak Alive?
by Zacks Equity Research
Edwards Lifesciences (EW) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.